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PSEUDOCHOLINESTERASE DEFICIENY
Ross Gerken, RN, BSN, CCRN, SRNA
Otterbein University, Westerville, Ohio
Introduction
Pseudocholinesterase deficiency is a
rare genetic or acquired variation in the
metabolism of choline esters such as the
neuromuscular blockers succinylcholine,
mivacurium, and ester local anesthetics.
Pseudocholinesterase deficiency
genetically is transmitted in an autosomal
recessive pattern with the frequency of
apnea from a genetic abnormality of
pseudocholinesterase between 1:480 and
1:3200 people (Ok et al., 2013). An
extended period of neuromuscular
blockade results from these medications
than what is clinically expected. The signs
and symptoms which occur are apnea and
paralysis hours longer. This condition is
rare but must be known and understood
by the clinician in order to provide the
safest patient care possible. The
information is not widely known or
readily available and usually is
undetected until the patient receives the
medications and then the neuromuscular
blockade continues well beyond the
expected duration. The purpose of this
discussion is to further educate the
practitioner on the pathophysiology of
pseudocholinesterase deficiency, as well
as signs and symptoms, and patient
management strategies to improve
patient outcomes.

Case Study
A 43 year old female is having
rotator cuff repair s/p rotator cuff tear.
She has no known drug allergies. Her
past medical history is GERD and
hypertension, which she takes 20mg
lisinopril and 20mg omeprazole. Past
surgical history is one C-section. Family
history of anesthetic problems: States
“thinks her dad may have had difficulty
waking up but was not sure”. Vitals:
blood pressure 128/86, heart rate 70,
SpO2 99% on room air, respirations 16,
temperature 98.40C. The patient had
general anesthesia, with standard
induction consisting of 80mg lidocaine,
150mg propofol, 5mg rocuronium, and
140mg succinylcholine. Sevoflurane 2%
was used for maintenance. Intraoperative course is uneventful. During
emergence patient remains apneic, with
no response to increase in C02. First
considerations must be differential
diagnoses for a delayed emergence.

Differential
Diagnosis

Pathophysiology
Cont.

Drug Effects:
•

Residual anesthetic, including over
sedation and large amounts of
narcotics.

Metabolic causes:
•
•
•
•
•

Hypothermia
Hypoglycemia
Hyponatremia
Hypoxia
Hypercarbia

Neurological causes:
•
•
•

Increased cerebral hemorrhage
resulting in increased intracranial
pressure
Ischemic episode
Seizure resulting in a post-ictal state

After further examination vital signs
were stable, blood glucose was 108, and
electrolytes were within normal limits.
However, train of four was assessed
resulting in 0/4 twitches, indicating
prolonged paralysis. This lead to the rare
conclusion of Pseudocholinesterase
deficiency. The major signs and
symptoms occurred postoperatively
after administration of the muscle
relaxant succinylcholine for induction
during surgery. The patient presented
with apnea, prolonged paralysis, and
weak or 0/4 twitches with the train of
four.

Pathophysiology
Pseudocholinesterase is an enzyme
produced in the liver. The heart, plasma,
pancreas, and the white matter also
contain pseudocholinesterase Ama et al.
(2010). The enzyme is responsible for
metabolizing succinylcholine,
mivacurium, and other ester local
anesthetics such as cocaine and procaine.
In people with normal
pseudocholinesterase levels, the
medications are usually hydrolyzed very
quickly, even before it reaches the
neuromuscular junction. According to
Ama et al. (2010), “this hydrolysis
rapidly inactivates around 90% to 95%
of the intravenous succinylcholine dose.

The remaining 5% to 10% of the
succinylcholine dose acts as an
acetylcholine receptor agonist at the
neuromuscular junction.” This causes
depolarization of skeletal muscle, which
results in fasciculations that can be
seen in the muscles. Once the
acetylcholine is released from the
presynaptic membrane, and the
remainder of the succinylcholine binds
to the receptors on the postsynaptic
neuromuscular junction, it is no longer
able to evoke any more action
potentials. This is what causes the
muscle paralysis. The paralysis can
develop as quickly as one minute.
Elimination of succinylcholine is
accomplished by pseudocholinesterase
enzyme diffusing the medication away
from the acetylcholine receptors. It is
first metabolized into
succinylmonocholine, which is 1/20th
to 1/90th as potent as succinylcholine
and then broken down to succinate and
choline Ama et al. (2010). Normally, a
patient recovers fully from
succinylcholine (0.5-1.0 mg/kg) within
5 minutes. However, a patient who has
pseudocholinesterase deficiency is
unable to metabolize the medication as
quickly as a person with normal levels.
This leads to increased number of
succinylcholine molecules in the
neuromuscular junction, causing the
duration of paralytic effect to continue
for up to 8 hours.

Dibucaine
Inhibition Test
Results

Nursing Implications

Diagnostic Test:
Dibucaine is an amide local
anesthetic that inhibits typical
pseudocholinesterase. Dibucane is added
to a sample of the patient’s serum and
compared to untreated serum to show
the sensitivity to succinylcholine. A
Dibucaine number and enzyme activity
are both determined. A normal result is
80. The results indicate Dibucaine
inhibits 80% of pseudocholinesterase
activity. A Dibucaine number of 20 is
diagnostic for atypical
pseudocholinesterase levels.

Conclusion
Continued
The most important issue is to keep
the patient safe and comfortable
throughout this experience. Always
remember just because the patient is
paralyzed does not mean they are not
aware or pain free. The patient must be
kept sedated with adequate pain control
until the prolonged paralysis resolves.

Treatment
Treatment is aimed at patient safety,
care and comfort. The standard of care is
to maintain sedation and ventilation
until return of normal neuromuscular
function and patient is able to protect
their airway. This is considered the
safest option. The other options are
transfusions of whole blood and FFP, or
purified human cholinesterase.
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